|
|
Commision globale de politique en matière de drogues (Ed.). (2014). Prendre le contrôle : sur la voie de politiques efficaces en matière de drogues. Genève: Commision globale de politique en matière de drogues.
Keywords: report; drug policy; impact of policy or law; law enforcement; legal regulation; war on drugs; international area; drug decriminalization; prevention; harm reduction; HIV infection; hepatitis C
|
|
|
|
Dickson-Spillmann, M., Hiltebrand, D., Bolliger, H., & Schaub, M. P. (2014). Heroingestützte Behandlung in der Schweiz (HeGeBe) : Resultate der Erhebung 2013 (Schweizer Institut für Sucht- und Gesundheitsforschung, Ed.). Zürich: Schweizer Institut für Sucht- und Gesundheitsforschung (ISGF).
Keywords: annual report; questionnaire; treatment and maintenance; heroin-assisted treatment; outpatient care; statistical data; AOD consumption; health; viral hepatitis; HIV infection
|
|
|
|
Laubereau, B., & Spörri, M. (2014). Möglichkeiten und Grenzen einer evidenzbasierten Beurteilung des illegalen Drogenkonsums in der Schweiz (Interface, Ed.). Zürich: Interface Politikstudien Forschung Beratung.
Abstract: Die vorliegende Untersuchung liefert für die Schweiz einen differenzierten Überblick über verfügbare Datenquellen und einen Einblick in Methoden zur Prävalenzschätzung des illegalen Drogenkonsums. Illegale Drogen wurden eingegrenzt auf Cannabis, Heroin, Kokain sowie die Partydrogen Amphetamine/Speed, Ecstasy und LSD. Ausgehend von einer Liste mit Datenquellen wurden diese zu Datentypen zusammengefasst und entlang einem neu entwickelten Schema «Kette des Drogenkonsums» verortet. Neun ausgewählte Datentypen wurden in Faktenblättern anhand einer Datenquelle differenziert beschrieben und hinsichtlich ihrer Eignung für Prävalenzschätzungen beurteilt. Zudem wurden drei methodische Ansätze der Europäischen Beobachtungsstelle für Drogen und Drogensucht zur Prävalenzschätzung (Multiplikationsmethode, Multiple Indicator Method, Capture-Recapture) im Kerngedanken beschrieben. Wir kommen zu dem Schluss, dass trotz offensichtlicher Grenzen von Prävalenzschätzungen hinreichend gute Zahlen, insbesondere zu negativen Folgen des Konsums und zu Entwicklungen über die Zeit, berechenbar sind. Inhaltliche Sachkompetenz ist für die Auswahl der Datenquellen und die Interpretation der Ergebnisse sehr wichtig. Für das weitere Vorgehen empfehlen wir die Formulierung konkreter Fragestellungen für die Prävalenzschätzung, den Einsatz von transparenten Berechnungsmethoden sowie eine Kreuzvalidierung der Ergebnisse und die Verbesserung der Datenlage hinsichtlich Partydrogen sowie bei jungen Erwachsenen. In einem abschliessenden Expertenworkshop wurden die Synthese und Empfehlungen grundsätzlich gutgeheissen und mögliche weitere Schritte diskutiert.
Keywords: report; research; statistical data; data analysis method; recommendations or guidelines; drug consumption; illegal drug use; prevalence; cannabis; cocaine; LSD; amphetamines; Ecstasy
|
|
|
|
various. (2013). Mental health and addiction in prisons : written contributions to the international conference on mental health and addiction in prisons (Co-operation Group to Combat Drug Abuse & Illicit Trafficking in Drugs, Ed.). Brussels: Pompidou Group; Council of Europe.
Keywords: mental health; AOD use; prison; AOD user; health care professionals; public health; communicable disease; HIV infection; viral hepatitis; treatment and maintenance; psychosocial treatment method; drug substitution therapy; art therapy; aftercare; statistical data; international area; Europe; report
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Models for the legal supply of cannabis : recent developments. Lisbon: Author.
Abstract: The international legal framework on drug control is provided by three United Nations Conventions, which instruct countries to limit drug supply and use to medical and scientific purposes. Nevertheless, there continues to be increasing debate over decriminalisation, or even legalisation, of drugs, and of cannabis in particular. Such proposals raise concerns over increases in use and harms and questions about the ways in which the distribution of cannabis for non-medical purposes could be carefully regulated to mitigate these. In the EU, a system of limited distribution has evolved in the Netherlands since the1970s, with further developments in 2012.
Keywords: laws and regulations; public policy on AOD; illicit drug; cannabis; drug decriminalization; drug legalization; harm reduction; AOD sales outlet; AOD supply; international area; Europe; European Union
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Emergency health consequences of cocaine use in Europe (European Monitoring Centre for Drugs and Drug Addiction, Ed.). Lisbon.
Abstract: Every year, several thousands of cocaine-related emergencies are reported in Europe, along with hundreds of cocaine-related deaths. The types of cocaine-related problems reported are wide ranging and the relatively high prevalence of cocaine use in the general population means that there is likely to be a significant impact on overall public health.
Keywords: public health; AOD use; prevalence; AOD effects and AODR problems; adverse drug effect; AOD induced risk; AODR mortality; emergency care; cocaine; Europe; European Union
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Controlling new psychoactive substances. Lisbon: Author.
Abstract: Recent years have witnessed a proliferation of new psychoactive substances becoming available in Europe. This can be illustrated through the rise in notifications of new substances to the EU early warning system, from just 14 per year in 2005 to 73 in 2012. Some of these substances will find their way on to the market, packaged and promoted as ’natural’ or ’legal’ products, in specialised physical and online shops. In particular, Internet sales of new drugs means that the expanding global network cuts across national boundaries and jurisdictions.
Keywords: public policy on AOD; laws and regulations; psychoactive substances; internet; AOD sales outlet; drug trafficking; international area; Europe; European Union
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Characteristics of frequent and high-risk cannabis users. Lisbon: Author.
Abstract: Cannabis is Europe’s most commonly used illicit drug, with approximately 20 million adults, or around 6% of the population aged 15-64 years, having used the drug in the last year. An indication of the public health impact of the drug can be seen in the numbers entering specialised treatment in Europe for drugrelated problems, among whom cannabisis the second most frequently reported drug, after heroin. Against this backdrop, identifying the characteristics of frequentand high-risk cannabis users can help with the identification and design of interventions for those cannabis users most at risk of experiencing problems.
Keywords: public health; public policy on AOD; intervention (persuasion to treatment); risk; AOD use pattern; illicit drug; cannabis; treatment and maintenance; statistical data; Europe; European Union
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Hepatitis C treatment for injecting drug users. Lisbon: Author.
Abstract: Hepatitis C is the most common infectious disease in injecting drug users, among whom it is usually transmitted through the sharing of injecting equipment such as needles and syringes. Most of those who become infected go on to develop chronic HCV infection, which can lead to severe health problems in individuals and place a major burden on health care systems. Yet hepatitis C is both preventable and curable, and interventions in this field, particularly the development of new medicines to treat hepatitis C, are making rapid progress.
Keywords: intravenous drug user; needle sharing; infection; viral hepatitis; hepatitis C; statistical data; Europe; European Union
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). The new EU drugs strategy (2013–20). Lisbon: Author.
Abstract: EU drugs strategies and action plans direct collective action in the field of drugs both within the European Union and at international level. They do not impose legal obligations on EU Member States but promote a shared model with defined priorities, objectives, actions and metrics for measuring performance. Member States, and also some candidate and pre-accession countries, use this framework to develop their own national policy documents, which are increasingly synchronised with the EU strategy. They remain free to emphasise different national priorities within the overall framework of an integrated, balanced andevidence-based approach to the drugs problem.
Keywords: government and politics; laws and regulations; legal regulation; drug laws; strategy; illicit drug; international area; Europe; European Union
|
|
